Second quarter 2022 net loss of $91.8 million, adjusted EBITDA of $50.5 million and cash flow available for distributions (“Distributable Cash Flow” or “DCF”) of $25.6 million Adjusted EBITDA was impacted by approximately $3.6 million of estimated weather-related interruptions in the…
Related Posts
EnergySource Minerals Selected by Compass Minerals as Direct Lithium Extraction Technology Provider
The latest selection underscores viability and lead position for EnergySource Minerals’ patented lithium brine extraction technology SAN DIEGO COUNTY, Calif.,…
Paul Boudre nommé chairman de UnitySC
MONTBONNOT, 23 septembre 2022 /PRNewswire/ — UnitySC, l’un des leaders des équipements de métrologie et d’inspection pour l’industrie des semi-conducteurs,…
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.
Pharma Desk, India: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivabradine Tablets, 5 mg and 7.5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, 5…
Read More “Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.” »
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.